# A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

> **NCT00744679** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 20 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT00744679
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744679, "A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00744679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*